drugset / Trial / NCT02431624

An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion

NCT02431624

Phase 1 Completed 40 enrolled Mundipharma Research Limited
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to assess the adhesion of BTDS patch 40 µg/h.

Timeline

Start
2015-03
Primary completion
2015-05
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 20 ug Other
Subject Buprenorphine Other / unclassified 40 ug Other

Indications

No indication recorded.